345 related articles for article (PubMed ID: 20061157)
1. 4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields.
Vitorović-Todorović MD; Juranić IO; Mandić LM; Drakulić BJ
Bioorg Med Chem; 2010 Feb; 18(3):1181-93. PubMed ID: 20061157
[TBL] [Abstract][Full Text] [Related]
2. Structural modifications of 4-aryl-4-oxo-2-aminylbutanamides and their acetyl- and butyrylcholinesterase inhibitory activity. Investigation of AChE-ligand interactions by docking calculations and molecular dynamics simulations.
Vitorović-Todorović MD; Koukoulitsa C; Juranić IO; Mandić LM; Drakulić BJ
Eur J Med Chem; 2014 Jun; 81():158-75. PubMed ID: 24836068
[TBL] [Abstract][Full Text] [Related]
3. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
Campiani G; Fattorusso C; Butini S; Gaeta A; Agnusdei M; Gemma S; Persico M; Catalanotti B; Savini L; Nacci V; Novellino E; Holloway HW; Greig NH; Belinskaya T; Fedorko JM; Saxena A
J Med Chem; 2005 Mar; 48(6):1919-29. PubMed ID: 15771436
[TBL] [Abstract][Full Text] [Related]
4. Docking and quantum mechanic studies on cholinesterases and their inhibitors.
Correa-Basurto J; Flores-Sandoval C; Marín-Cruz J; Rojo-Domínguez A; Espinoza-Fonseca LM; Trujillo-Ferrara JG
Eur J Med Chem; 2007 Jan; 42(1):10-9. PubMed ID: 17055616
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type.
Kapková P; Stiefl N; Sürig U; Engels B; Baumann K; Holzgrabe U
Arch Pharm (Weinheim); 2003 Nov; 336(11):523-40. PubMed ID: 14639745
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors.
Sheng R; Lin X; Zhang J; Chol KS; Huang W; Yang B; He Q; Hu Y
Bioorg Med Chem; 2009 Sep; 17(18):6692-8. PubMed ID: 19692250
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
Huang L; Shi A; He F; Li X
Bioorg Med Chem; 2010 Feb; 18(3):1244-51. PubMed ID: 20056426
[TBL] [Abstract][Full Text] [Related]
8. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors.
Asadipour A; Alipour M; Jafari M; Khoobi M; Emami S; Nadri H; Sakhteman A; Moradi A; Sheibani V; Homayouni Moghadam F; Shafiee A; Foroumadi A
Eur J Med Chem; 2013; 70():623-30. PubMed ID: 24211638
[TBL] [Abstract][Full Text] [Related]
9. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Scarpellini M; Viayna E; Badia A; Clos MV; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Estelrich J; Lizondo M; Bidon-Chanal A; Luque FJ
J Med Chem; 2008 Jun; 51(12):3588-98. PubMed ID: 18517184
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
Bolognesi ML; Bartolini M; Cavalli A; Andrisano V; Rosini M; Minarini A; Melchiorre C
J Med Chem; 2004 Nov; 47(24):5945-52. PubMed ID: 15537349
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities.
Zhan ZJ; Bian HL; Wang JW; Shan WG
Bioorg Med Chem Lett; 2010 Mar; 20(5):1532-4. PubMed ID: 20144867
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine.
Tumiatti V; Rosini M; Bartolini M; Cavalli A; Marucci G; Andrisano V; Angeli P; Banzi R; Minarini A; Recanatini M; Melchiorre C
J Med Chem; 2003 Mar; 46(6):954-66. PubMed ID: 12620072
[TBL] [Abstract][Full Text] [Related]
13. Preparation, anticholinesterase activity and molecular docking of new lupane derivatives.
Castro MJ; Richmond V; Romero C; Maier MS; Estévez-Braun A; Ravelo AG; Faraoni MB; Murray AP
Bioorg Med Chem; 2014 Jul; 22(13):3341-50. PubMed ID: 24835788
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
15. Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors.
Carolan CG; Dillon GP; Gaynor JM; Reidy S; Ryder SA; Khan D; Marquez JF; Gilmer JF
J Med Chem; 2008 Oct; 51(20):6400-9. PubMed ID: 18817366
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
Pan L; Tan JH; Hou JQ; Huang SL; Gu LQ; Huang ZS
Bioorg Med Chem Lett; 2008 Jul; 18(13):3790-3. PubMed ID: 18524585
[TBL] [Abstract][Full Text] [Related]
17. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
Musilek K; Komloova M; Zavadova V; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K; Jung YS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1763-6. PubMed ID: 20138518
[TBL] [Abstract][Full Text] [Related]
18. Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase.
Decker M; Krauth F; Lehmann J
Bioorg Med Chem; 2006 Mar; 14(6):1966-77. PubMed ID: 16289855
[TBL] [Abstract][Full Text] [Related]
19. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
[TBL] [Abstract][Full Text] [Related]
20. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B.
He XC; Feng S; Wang ZF; Shi Y; Zheng S; Xia Y; Jiang H; Tang XC; Bai D
Bioorg Med Chem; 2007 Feb; 15(3):1394-408. PubMed ID: 17126020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
